| INTRODUCTION
Mycosis fungoides is a form of cutaneous T-cell lymphoma that follows a predominantly indolent course. 1 In approximately 20% to 50% of cases, the disease undergoes large cell transformation, which is defined as the presence of large cells (>4 times the size of a small lymphocyte) exceeding 25% of the infiltrate, or formation of microscopic nodules. 2, 3 This form of the disease has a more aggressive clinical course with a reduction in overall patient survival and therefore accurate diagnosis is critical for appropriate patient management. 2, [4] [5] [6] [7] [8] However, there are many diagnostic challenges in making the correct diagnosis. For example, in situations where the percentage of large cells is between 20% to 30%, histological confirmation alone may be challenging. Furthermore, immunohistochemistry for CD30, while useful as a therapeutic target, is not a reliable nor a specific marker for large cell transformation. 3, [9] [10] [11] [12] [13] [14] [15] Ki-67, a cell-cycle marker associated with proliferating cells, has been studied in a limited fashion with respect to mycosis fungoides.
One study found a mean Ki-67 staining of non-transformed mycosis fungoides to be 13% in the dermis and 14% in the epidermis. 16 To the best of our knowledge, no studies to date have directly compared
Ki-67 staining between mycosis fungoides with and without large cell transformation. From our experience, we hypothesize that patients with large cell transformation will have an elevated Ki-67 index, and overall, Ki-67 will be a useful indicator for large cell transformation.
TP53 (p53) is a tumor suppressor gene located on the short arm of chromosome 17, and has been described in a wide variety of carcinomas, sarcomas, and leukemias/lymphomas. 17 It is often referred to as the "guardian of the genome" as p53 modulates the cell cycle and initiates apoptosis in response to DNA damage. 18, 19 Numerous studies have examined the relationship between p53 and mycosis fungoides with respect to disease progression, prognosis, and large cell transformation, although the results are not always consistent. [20] [21] [22] [23] With the benefit of being a large tertiary referral center with an expert cutaneous lymphoma clinic with extensive clinical annotation, we aim to explore whether p53 and Ki-67 immunohistochemistry can be useful and readily available ancillary studies to promote accurate diagnosis of large cell transformation in mycosis fungoides. 
| MATERIALS AND METHODS

| Cohorts
| Immunohistochemistry
For each biopsy, a hematoxylin and eosin (H&E) stained slide was created prior to proceeding with immunohistochemistry. These slides were reviewed by a dermatopathologist in all cases (JK) and established diagnoses were confirmed. Subsequently, 5 μm thick tissue sections were cut, deparaffinized, and rehydrated. Slides were then stained for CD30 (Dako, Carpinteria, California), Ki-67 (Dako, Carpinteria, California), and p53 (Dako, Carpinteria, California). Detection was performed with the Bond Polymer Refine Detection System (Leica Biosystems, UK).
Each immunohistochemical stain was reviewed and reported by two pathologists (JK and SR). CD30 was reported in percentage (%) of the lymphocytes with positive membranous staining. Ki-67 was reported in percentage (%) of the lymphocytes with positive nuclear staining. p53 was scored in a two-part, multi-tier grading system, evaluating the total percentage (%) of lymphocytes with nuclear staining as well of the intensity of nuclear staining on a 1+ to 4+ range.
| Statistics
Comparisons of CD30 and Ki-67 expression between the different groups were calculated using the non-parametric Mann-Whitney U test. Comparison of p53 expression was calculated using the χ 2 test.
All analyses were performed using Microsoft Excel (Microsoft Corporation, Seattle, Washington).
3 | RESULTS Overall, the average staining in this group was 22% for CD30 and 57% for Ki-67. This was statistically significant (P < 0.05) when Within the control group, all biopsy samples had 1+ staining in 10% to 40% of the lesional lymphocytes. In the large cell transformation group, 21 of 46 specimens had p53 staining of 2+ or higher, with seven containing intense 4+ staining. The difference between the two groups was statistically significant (0% vs 47%, P < 0.05). All four biopsy specimens in this group with epidermal ulceration contained positive p53 staining. Representative images are shown in Figure 3 .
| Clinicopathological findings
| Histology and immunohistochemistry
An overall data summary is shown in Figure 4 .
| DISCUSSION
Having the benefit of being a large referral center for the diagnosis and management of cutaneous lymphomas, our study is the largest staining in greater than 75% of cells. 27 The results in our study show that the average CD30 staining in mycosis fungoides to be 4% and 22% in mycosis fungoides with large cell transformation (P < 0.05).
This is similar to the findings by Talpur et al. 28 While these findings are statistically significant, in our experience, it is extremely difficult to rely on CD30 alone to make a diagnosis of large cell transformation as the average staining between the two groups is especially close and, in fact, some cases of LCT are completely negative for CD30. Overall, CD30 immunohistochemical staining is an insufficient criterion for supporting the diagnosis of large cell transformation.
In our study, Ki-67 proved to be a useful and statistically significant immunostain associated with large cell transformation (13% vs 57%, P ≤ 0.005). Interestingly, enlarged neoplastic lymphocytes within the epidermis showed strong diffuse expression in Pautrier microabscesses ( Figure 2 ). In a study of non-transformed mycosis fungoides, Edinger et al. showed Ki-67 staining of 14% in epidermis and 13% in dermis, which is similar to our observations. 16 The difference in prolif- Comparison of CD30, Ki-67 and p53 expression between mycosis fungoides and mycosis fungoides with large cell transformation. The above figure summarizes the overall immunohistochemical characteristics between the two groups. With respect to CD30, the control group averaged 4% staining while the large cell transformation group averaged 22% (P < 0.05). With respect to Ki-67, the control group averaged 13%, while the large cell transformation group averaged 57% (P < 0.05). The control group did not show any positive staining for p53 (all designated "wild type" see Figure 3 ), while 47% percent of the large cell transformation group was positive (P < 0.05). Error bars shown represent SE FIGURE 5 Co-localization of Ki-67 and p53 in a patient with mycosis fungoides with large cell transformation. These images are from biopsy #26 (patient 22). A, Hematoxylin and eosin stained slide shown at 60×. B, Ki-67 stained slide shown at 60×; this was quantified at 60%. (C) 4+, 40% p53 staining shown at 60× lymphocytes). In our limited study, it is difficult to definitively determine whether p53 plays a direct role in large cell transformation, or whether p53 dysfunction is a molecular marker for large cell transformation.
All four cases having epidermal ulceration in the transformed group contained increased p53 staining, and 2 of the 4 showed robust 4+ staining. This group was also characterized by an average Ki-67 of 73%, and there appeared to be substantial co-localization ( Figure 5 ).
Larger prospective studies are required to definitively determine the clinical significance. Nonetheless, p53 immunohistochemistry can play a similar role as Ki-67 in assisting one to make a diagnosis of large cell transformation, especially in the in the challenging case of 20% to 30% large cells. We aim to continue this study with a larger prospective cohort and continued to follow up to determine if Ki-67 or p53 expression correlates with meaningful clinical prognostic information in a multivariate model.
CONFLICTS OF INTEREST
The authors have no conflicts of interest to report.
ORCID
Jinah Kim
https://orcid.org/0000-0002-5065-5916
